{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:35:07Z","timestamp":1766050507375,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tecnimede, SA"},{"DOI":"10.13039\/501100005727","name":"Universidade de Coimbra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005727","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ibandronate is effective in reducing the risk of vertebral fractures, but experimental evidence offers conflicting results regarding nonvertebral fractures. Real-world evidence has been published evaluating the anti-nonvertebral fracture effect of ibandronate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>This meta-analysis of observational studies assessed the effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Pubmed\/Embase databases were searched for observational studies. Risks of nonvertebral fractures and hip fractures were the outcomes. Meta-analyses were performed pooling rate ratios (RRs), using random-effects models. Data were reanalysed in sensitivity analyses considering Knapp\u2013Hartung method and Bayesian random-effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Six cohort studies were included. Overall, once-monthly 150\u00a0mg oral ibandronate reduced the risk of nonvertebral fractures (RR 0.84; 95% CI 0.76\u20130.94). Similar results were obtained when the comparison was restricted to once-monthly 150\u00a0mg risedronate, but no differences were found when the comparator was other oral bisphosphonates (weekly alendronate\/risedronate). Ibandronate didn\u2019t significantly change the risk of hip fractures (RR 1.25; 95% CI 0.89\u20131.76). The risk of hip fracture was comparable between once monthly, 150\u00a0mg oral ibandronate and other oral bisphosphonates. Intravenous ibandronate was not effective in reducing hip fractures comparing to intravenous zoledronate. The low number of studies diminished the robustness of sensitivity analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Results suggest that once-monthly 150\u00a0mg oral ibandronate may be as effective as other oral bisphosphonates in reducing the risk of nonvertebral fractures. However, uncertainty associated to the small number of included studies, which are characterized by heterogeneous demographics and methodologies, precluded definitive conclusions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11096-023-01666-x","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T13:01:56Z","timestamp":1702990916000},"page":"357-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2814-3049","authenticated-orcid":false,"given":"Carlos","family":"Alves","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-8717","authenticated-orcid":false,"given":"Diogo","family":"Mendes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2061-4718","authenticated-orcid":false,"given":"Ana","family":"Penedones","sequence":"additional","affiliation":[]},{"given":"T\u00e2nia","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio","family":"Donato","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4031-7339","authenticated-orcid":false,"given":"Francisco","family":"Batel-Marques","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"issue":"5","key":"1666_CR1","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595\u2013622.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1666_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/GME.0000000000001831","volume":"28","author":"J Blake","year":"2021","unstructured":"Blake J, Cosman FA, Lewiecki EM, et al. Management of osteoporosis in postmenopausal women: The 2021 position statement of The North American Menopause Society. Menopause. 2021;28(9):973\u201397.","journal-title":"Menopause"},{"issue":"9","key":"1666_CR3","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032\u201345.","journal-title":"Mayo Clin Proc"},{"key":"1666_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bone.2016.05.013","volume":"89","author":"J Sanderson","year":"2016","unstructured":"Sanderson J, Martyn-St James M, Stevens J, et al. Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: a systematic review and network meta-analysis. Bone. 2016;89:52\u20138.","journal-title":"Bone"},{"issue":"8","key":"1666_CR5","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut 3rd","year":"2004","unstructured":"Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241\u20139.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"1666_CR6","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1359\/JBMR.050313","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20(8):1315\u201322.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1666_CR7","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"PD Delmas","year":"2006","unstructured":"Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54(6):1838\u201346.","journal-title":"Arthritis Rheum"},{"key":"1666_CR8","unstructured":"European Medicines Agency. Summary of Product Characteristics of Bonviva\u00ae. December 18, 2013. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bonviva-epar-product-information_en.pdf. Accessed  4 Oct  2023."},{"issue":"12","key":"1666_CR9","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s00198-012-1935-8","volume":"23","author":"C Roux","year":"2012","unstructured":"Roux C, Wyman A, Hooven FH, et al. Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int. 2012;23(12):2863\u201371.","journal-title":"Osteoporos Int"},{"issue":"9","key":"1666_CR10","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4065\/mcp.2010.0082","volume":"85","author":"JD Adachi","year":"2010","unstructured":"Adachi JD, Adami S, Gehlbach S, et al. Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc. 2010;85(9):806\u201313.","journal-title":"Mayo Clin Proc"},{"key":"1666_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bonr.2016.07.005","volume":"5","author":"D Weycker","year":"2016","unstructured":"Weycker D, Li X, Barron R, et al. Hospitalizations for osteoporosis-related fractures: economic costs and clinical outcomes. Bone Rep. 2016;5:186\u201391.","journal-title":"Bone Rep"},{"issue":"2","key":"1666_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00198-008-0653-8","volume":"20","author":"A Cranney","year":"2009","unstructured":"Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int. 2009;20(2):291\u20137. https:\/\/doi.org\/10.1007\/s00198-008-0653-8.","journal-title":"Osteoporos Int"},{"issue":"1","key":"1666_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1185\/030079908X253717","volume":"24","author":"ST Harris","year":"2008","unstructured":"Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008;24(1):237\u201345.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1666_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12891-019-2769-8","volume":"20","author":"YZ Jin","year":"2019","unstructured":"Jin YZ, Lee JH, Xu B, et al. Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2019;20(1):399.","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"1666_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00198-018-4778-0","volume":"30","author":"DR Lee","year":"2019","unstructured":"Lee DR, Lee J. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study. Osteoporos Int. 2019;30(3):659\u201366.","journal-title":"Osteoporos Int"},{"issue":"3","key":"1666_CR16","first-page":"302","volume":"33","author":"H Yun","year":"2015","unstructured":"Yun H, Delzell E, Saag KG, et al. Fractures and mortality in relation to different osteoporosis treatments. Clin Exp Rheumatol. 2015;33(3):302\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1666_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.189","volume":"26","author":"ES Siris","year":"2011","unstructured":"Siris ES, Pasquale MK, Wang Y, et al. Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001\u20132008. J Bone Miner Res. 2011;26(1):3\u201311.","journal-title":"J Bone Miner Res"},{"key":"1666_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"1666_CR19","unstructured":"University of York, Centre for Reviews and Dissemination. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. January 2009. https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf. Accessed 4 Oct 2023."},{"issue":"2","key":"1666_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/RHU.0000000000001902","volume":"29","author":"D Mendes","year":"2023","unstructured":"Mendes D, Penedones A, Alves C, et al. Ibandronate in the prevention of vertebral and nonvertebral osteoporotic fractures: a systematic review of experimental and observational studies. J Clin Rheumatol. 2023;29(2):78\u201383.","journal-title":"J Clin Rheumatol"},{"key":"1666_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.","journal-title":"BMJ"},{"issue":"3","key":"1666_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"7414","key":"1666_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"key":"1666_CR24","doi-asserted-by":"crossref","unstructured":"Publication bias. In: Borenstein M, Hedges LV, JPT H, Rothstein HR, editors. Introduction to meta-analysis. Wiley, Chichester, pp 277\u2013291. 2009.","DOI":"10.1002\/9780470743386"},{"issue":"3","key":"1666_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/jrsm.1297","volume":"9","author":"R Bender","year":"2018","unstructured":"Bender R, Friede T, Koch A, et al. Methods for evidence synthesis in the case of very few studies. Res Synth Methods. 2018;9(3):382\u201392.","journal-title":"Res Synth Methods"},{"key":"1666_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2022.107303","volume":"229","author":"C R\u00f6ver","year":"2023","unstructured":"R\u00f6ver C, Friede T. Using the bayesmeta R package for Bayesian random-effects meta-regression. Comput Methods Programs Biomed. 2023;229: 107303.","journal-title":"Comput Methods Programs Biomed"},{"issue":"6","key":"1666_CR27","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00198-009-1046-3","volume":"21","author":"A Abelson","year":"2010","unstructured":"Abelson A, Ringe JD, Gold DT, et al. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int. 2010;21(6):1021\u20139.","journal-title":"Osteoporos Int"},{"issue":"5","key":"1666_CR28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.bone.2009.01.002","volume":"44","author":"ST Harris","year":"2009","unstructured":"Harris ST, Reginster JY, Harley C, et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone. 2009;44(5):758\u201365.","journal-title":"Bone"},{"key":"1666_CR29","doi-asserted-by":"crossref","unstructured":"O'Kelly J, Bartsch R, Kossack N, et al. Real-world effectiveness of osteoporosis treatments in Germany [published correction appears in Arch Osteoporos. 2022;17(1):129]. Arch Osteoporos 2022;17(1):119.","DOI":"10.1007\/s11657-022-01167-w"},{"key":"1666_CR30","unstructured":"Cochrane Editorial and Publishing Policy Resource. Policy: Cochrane Review updates. June 30, 2021. https:\/\/documentation.cochrane.org\/display\/EPPR\/Policy%3A+Cochrane+Review+updates. Accessed 4 Oct  2023."},{"key":"1666_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3507","volume":"354","author":"P Garner","year":"2016","unstructured":"Garner P, Hopewell S, Chandler J, et al. When and how to update systematic reviews: consensus and checklist. BMJ. 2016;354: i3507.","journal-title":"BMJ"},{"issue":"4","key":"1666_CR32","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s11096-023-01586-w","volume":"45","author":"C Laird","year":"2023","unstructured":"Laird C, Williams KA, Benson H. Perceptions and practices of aged care pharmacists regarding osteoporosis management: a qualitative study. Int J Clin Pharm. 2023;45(4):913\u201321.","journal-title":"Int J Clin Pharm"},{"key":"1666_CR33","unstructured":"Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions\u00a0version 6.4. August 2023. www.training.cochrane.org\/handbook. Accessed October 4, 2023."},{"key":"1666_CR34","doi-asserted-by":"crossref","unstructured":"Houle S. An introduction to the fundamentals of randomized controlled trials in pharmacy research. Can J Hosp Pharm. 2015;68(1):28\u201332.","DOI":"10.4212\/cjhp.v68i1.1422"},{"issue":"10","key":"1666_CR35","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00228-019-02713-1","volume":"75","author":"C Alves","year":"2019","unstructured":"Alves C, Mendes D, Marques FB. Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2019;75(10):1431\u201343.","journal-title":"Eur J Clin Pharmacol"},{"key":"1666_CR36","unstructured":"European Medicines Agency. Summary of Product Characteristics of Fosavance\u00ae. April 24, 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fosavance-epar-product-information_en.pdf. Accessed 4 Oct  2023."},{"key":"1666_CR37","unstructured":"Medicines & Healthcare products Regulatory Agency. Summary of Product Characteristics of Actonel\u00ae. January 14, 2016. https:\/\/products.mhra.gov.uk\/product\/?product=ACTONEL%20ONCE%20A%20WEEK%2035%20MG%20FILM-COATED%20TABLETS. Accessed 4 Oct 2023."},{"issue":"5","key":"1666_CR38","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis. J Clin Endocrinol Metab. 2019;104(5):1623\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"1666_CR39","doi-asserted-by":"crossref","unstructured":"Jansen JP, Bergman GJ, Huels J, et al. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum. 2011;40(4):275\u201384.e1\u20132.","DOI":"10.1016\/j.semarthrit.2010.06.001"},{"issue":"1","key":"1666_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11657-019-0678-y","volume":"15","author":"TA Kanters","year":"2020","unstructured":"Kanters TA, van de Ree CLP, de Jongh MAC, et al. Burden of illness of hip fractures in elderly Dutch patients. Arch Osteoporos. 2020;15(1):11.","journal-title":"Arch Osteoporos"},{"key":"1666_CR41","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the Evaluation of Medicinal Products in the Treatment of Primary Osteoporosis. November 16, 2006. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-medicinal-products-treatment-primary-osteoporosis_en.pdf. Accessed 4 Oct  2023."},{"key":"1666_CR42","doi-asserted-by":"publisher","unstructured":"Kempen TGH, Koumi R, Sporrong SK. Pharmacists in general practice: what do they do? A qualitative case study. Int J Clin Pharm. 2023. doi: https:\/\/doi.org\/10.1007\/s11096-023-01619-4.","DOI":"10.1007\/s11096-023-01619-4"},{"issue":"8","key":"1666_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","volume":"8","author":"DM Black","year":"2020","unstructured":"Black DM, Bauer DC, Vittinghoff E, et al. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8(8):672\u201382.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1666_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jbmr.4433","volume":"37","author":"R Eastell","year":"2022","unstructured":"Eastell R, Vittinghoff E, Lui LY, et al. Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. J Bone Miner Res. 2022;37(1):29\u201335.","journal-title":"J Bone Miner Res"},{"key":"1666_CR45","unstructured":"European Medicines Agency. Evaluation of new medicinal products in the treatment of primary osteoporosis. CPMP\/EWP\/552\/95 Rev. 2. May 31, 2007. https:\/\/www.ema.europa.eu\/en\/evaluation-new-medicinal-products-treatment-primary-osteoporosis. Accessed  4 Oct 2023."},{"issue":"5","key":"1666_CR46","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00774-020-01096-z","volume":"38","author":"T Tsuda","year":"2020","unstructured":"Tsuda T, Hashimoto Y, Okamoto Y, et al. Meta-analysis for the efficacy of bisphosphonates on hip fracture prevention. J Bone Miner Metab. 2020;38(5):678\u201386.","journal-title":"J Bone Miner Metab"},{"key":"1666_CR47","doi-asserted-by":"publisher","first-page":"215145932098036","DOI":"10.1177\/2151459320980369","volume":"11","author":"DW Barton","year":"2020","unstructured":"Barton DW, Smith CT, Piple AS, et al. Timing of Bisphosphonate Initiation After Fracture: What Does the Data Really Say? Geriatr Orthop Surg Rehabil. 2020;11:2151459320980369.","journal-title":"Geriatr Orthop Surg Rehabil"},{"issue":"3","key":"1666_CR48","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00198-019-04852-8","volume":"30","author":"J Banefelt","year":"2019","unstructured":"Banefelt J, \u00c5kesson KE, Sp\u00e5ng\u00e9us A, et al. Risk of imminent fracture following a previous fracture in a Swedish database study. Osteoporos Int. 2019;30(3):601\u20139.","journal-title":"Osteoporos Int"},{"key":"1666_CR49","unstructured":"Elsevier. Embase content coverage. August 2023. https:\/\/www.elsevier.com\/solutions\/embase-biomedical-research\/coverage-and-content. Accessed 4 Oct  2023."},{"key":"1666_CR50","unstructured":"National Institute of Health (NIH). National Library of Medicine. PubMed Overview. August 15, 2023. https:\/\/pubmed.ncbi.nlm.nih.gov\/about\/. Accessed 4 Oct  2023."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-023-01666-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-023-01666-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T15:03:12Z","timestamp":1711206192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-023-01666-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1007\/s11096-023-01666-x","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"25 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ant\u00f3nio Donato and T\u00e2nia Oliveira are employees of Tecnimede, SA. There is no other conflict of interests do declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}